Literature DB >> 8762019

Prolonged islet allograft acceptance in the absence of interleukin 4 expression.

P Nickerson1, X X Zheng, J Steiger, A W Steele, W Steurer, P Roy-Chaudhury, W Müller, T B Strom.   

Abstract

Murine CTLA4/Fc therapy leads to permanent engraftment of islet allografts in interleukin 4 (IL-4) knockout (IL-4-/- mice. Interestingly, IL-4+/- hosts were more resistant to tolerance induction than IL-4-/- mice. An IL-2/Fc fusion protein abrogates the effect of CTLA4/Fc therapy while an IL-4/Fc fusion protein tends to inhibit rather than enhance the effect of CTLA/Fc treatment in IL-4-/- recipients. We conclude that allograft acceptance requires principally a blockade of T cell activation rather than 'immune deviation' of the T cell activation program to Th2 cytokines (i.e. IL-4).

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8762019     DOI： 10.1016/s0966-3274(96)80043-8

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN： 0966-3274            Impact factor:   1.708


  8 in total

1.  Requirement for natural killer T (NKT) cells in the induction of allograft tolerance.

Authors:  K I Seino; K Fukao; K Muramoto; K Yanagisawa; Y Takada; S Kakuta; Y Iwakura; L Van Kaer; K Takeda; T Nakayama; M Taniguchi; H Bashuda; H Yagita; K Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

2.  Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions.

Authors:  Cécile Taflin; Benoit Favier; Jeremy Baudhuin; Alain Savenay; Patrice Hemon; Armand Bensussan; Dominique Charron; Denis Glotz; Nuala Mooney
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

3.  Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fc gamma2a protein blocks delayed-type hypersensitivity.

Authors:  Y S Kim; W Maslinski; X X Zheng; A C Stevens; X C Li; G H Tesch; V R Kelley; T B Strom
Journal:  J Immunol       Date:  1998-06-15       Impact factor: 5.422

4.  On histocompatibility barriers, Th1 to Th2 immune deviation, and the nature of the allograft responses.

Authors:  X C Li; M S Zand; Y Li; X X Zheng; T B Strom
Journal:  J Immunol       Date:  1998-09-01       Impact factor: 5.422

5.  Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys.

Authors:  D H Barouch; A Craiu; M J Kuroda; J E Schmitz; X X Zheng; S Santra; J D Frost; G R Krivulka; M A Lifton; C L Crabbs; G Heidecker; H C Perry; M E Davies; H Xie; C E Nickerson; T D Steenbeke; C I Lord; D C Montefiori; T B Strom; J W Shiver; M G Lewis; N L Letvin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

6.  Antibody-mediated targeting of CD45 isoforms: a novel immunotherapeutic strategy.

Authors:  G P Basadonna; L Auersvald; C Q Khuong; X X Zheng; N Kashio; D Zekzer; M Minozzo; H Qian; L Visser; A Diepstra; A I Lazarovits; S Poppema; T B Strom; D M Rothstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

7.  Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4.

Authors:  T G Markees; N E Phillips; E J Gordon; R J Noelle; L D Shultz; J P Mordes; D L Greiner; A A Rossini
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

8.  A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy.

Authors:  Xueli Yuan; Jesus Paez-Cortez; Isabela Schmitt-Knosalla; Francesca D'Addio; Bechara Mfarrej; Michela Donnarumma; Antje Habicht; Michael R Clarkson; John Iacomini; Laurie H Glimcher; Mohamed H Sayegh; M Javeed Ansari
Journal:  J Exp Med       Date:  2008-12-01       Impact factor: 14.307
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.